Inflammatory Biomarkers and Respiratory Function in Liver Transplant Patients: Findings from a Nationwide Cohort Analysis
Clinical Scorecard: Inflammatory Biomarkers and Respiratory Function in Liver Transplant Patients: Findings from a Nationwide Cohort Analysis
At a Glance
Category Detail
Condition Impaired lung function in liver transplant recipients Key Mechanisms Elevated inflammatory markers, particularly hs-CRP, associated with lung function impairment Target Population Adult liver transplant recipients Care Setting Outpatient clinics for liver transplant recipients in Denmark
Key Highlights
11.6% prevalence of airflow limitation and 24.5% of PRISm in liver transplant recipients Median FEV1 of 2790 mL and median FVC of 3680 mL hs-CRP >3 mg/L linked to increased odds of PRISm and lower FEV1 and FVC Study utilized data from the DACOLT study, including >75% of eligible liver transplant recipients in Denmark Systemic inflammation may contribute to lung function impairment in this population Guideline-Based Recommendations
Diagnosis
Assess lung function using spirometry in liver transplant recipients Monitor inflammatory markers such as hs-CRP Management
Consider managing systemic inflammation to potentially improve lung function Regular follow-up for pulmonary function tests in liver transplant patients Monitoring & Follow-up
Monitor FEV1 and FVC in liver transplant recipients Evaluate hs-CRP levels as part of routine assessments Risks
Increased risk of pulmonary infections due to immunosuppressive therapy Potential for chronic pulmonary diseases in liver transplant recipients Patient & Prescribing Data
Adult liver transplant recipients with available spirometry and inflammatory marker data
Elevated hs-CRP levels may indicate the need for closer monitoring and management of lung function
Clinical Best Practices
Incorporate routine spirometry in the follow-up care of liver transplant recipients Evaluate and address systemic inflammation in liver transplant patients References
